Literature DB >> 21757972

Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma.

Ji Kon Ryu1, Hanno Matthaei, Marco Dal Molin, Seung-Mo Hong, Marcia I Canto, Richard D Schulick, Christopher Wolfgang, Michael G Goggins, Ralph H Hruban, Leslie Cope, Anirban Maitra.   

Abstract

BACKGROUND: Biomarkers for the diagnostic classification of pancreatic cysts are urgently needed. Deregulated microRNA (miRNAs) expression is widespread in pancreatic cancer. We assessed whether aberrant miRNAs in pancreatic cyst fluid could be used as potential biomarkers for cystic precursor lesions of pancreatic cancer.
METHODS: Cyst fluid specimens were prospectively collected from 40 surgically resected pancreatic cysts, and small RNAs were extracted. The 'mucinous' cohort included 14 intraductal papillary mucinous neoplasms (including 3 with an associated adenocarcinoma) and 10 mucinous cystic neoplasms; the 'nonmucinous' cohort included 11 serous cystadenomas and 5 other benign cysts. Quantitative reverse transcription PCR was performed for five miRNAs (miR-21, miR-155, miR-221, miR-17-3p, miR-191), which were previously reported as overexpressed in pancreatic adenocarcinomas.
RESULTS: Significantly higher expression of miR-21, miR-221, and miR-17-3p was observed in the mucinous versus nonmucinous cysts (p < 0.01), with the mean relative fold differences being 7.0-, 7.9-, and 5.4-fold, respectively. Receiver operating characteristic curves demonstrated the highest median area under the curve for miR-21, with a median specificity of 76%, at a sensitivity of 80%.
CONCLUSION: This pilot study demonstrates that profiling miRNAs in pancreatic cyst fluid samples is feasible and can yield potential biomarkers for the classification of cystic lesions of the pancreas. and IAP.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757972      PMCID: PMC3142103          DOI: 10.1159/000329183

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  56 in total

1.  Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis.

Authors:  Jordan M Winter; John L Cameron; Keith D Lillemoe; Kurtis A Campbell; David Chang; Taylor S Riall; Joann Coleman; Patricia K Sauter; Marcia Canto; Ralph H Hruban; Richard D Schulick; Michael A Choti; Charles J Yeo
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

Review 2.  Strategies for screening for pancreatic adenocarcinoma in high-risk patients.

Authors:  Marcia Irene Canto
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

3.  The pancreatic cyst incidentaloma: management consensus?

Authors:  Eugene P DiMagno
Journal:  Clin Gastroenterol Hepatol       Date:  2007-07       Impact factor: 11.382

4.  PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Nancy T Ciau; Daniel J Ho; Xiaojun Li; John D Allendorf; Helen E Remotti; Gloria H Su
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

5.  Expression profiling identifies microRNA signature in pancreatic cancer.

Authors:  Eun Joo Lee; Yuriy Gusev; Jinmai Jiang; Gerard J Nuovo; Megan R Lerner; Wendy L Frankel; Daniel L Morgan; Russell G Postier; Daniel J Brackett; Thomas D Schmittgen
Journal:  Int J Cancer       Date:  2007-03-01       Impact factor: 7.396

6.  MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.

Authors:  A E Szafranska; T S Davison; J John; T Cannon; B Sipos; A Maghnouj; E Labourier; S A Hahn
Journal:  Oncogene       Date:  2007-01-22       Impact factor: 9.867

7.  The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology.

Authors:  Asif Khalid; Kevin M McGrath; Maliha Zahid; Matt Wilson; Debra Brody; Patricia Swalsky; Arthur J Moser; Kenneth K Lee; Adam Slivka; David C Whitcomb; Sydney Finkelstein
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

Review 8.  ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts.

Authors:  Asif Khalid; William Brugge
Journal:  Am J Gastroenterol       Date:  2007-08-31       Impact factor: 10.864

9.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

Authors:  Mark Bloomston; Wendy L Frankel; Fabio Petrocca; Stefano Volinia; Hansjuerg Alder; John P Hagan; Chang-Gong Liu; Darshna Bhatt; Cristian Taccioli; Carlo M Croce
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

Review 10.  Precursor lesions of pancreatic cancer: molecular pathology and clinical implications.

Authors:  Mansher Singh; Anirban Maitra
Journal:  Pancreatology       Date:  2007-04-18       Impact factor: 3.996

View more
  48 in total

1.  miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts.

Authors:  Hanno Matthaei; Dennis Wylie; Maura B Lloyd; Marco Dal Molin; Jon Kemppainen; Skye C Mayo; Christopher L Wolfgang; Richard D Schulick; Laura Langfield; Bernard F Andruss; Alex T Adai; Ralph H Hruban; Anna E Szafranska-Schwarzbach; Anirban Maitra
Journal:  Clin Cancer Res       Date:  2012-06-21       Impact factor: 12.531

2.  851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital.

Authors:  Nakul P Valsangkar; Vicente Morales-Oyarvide; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

Review 3.  Novel Biomarkers for Pancreatic Cysts.

Authors:  Harkirat Singh; Kevin McGrath; Aatur D Singhi
Journal:  Dig Dis Sci       Date:  2017-02-14       Impact factor: 3.199

4.  Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.

Authors:  Yue Zhao; Lu Zhao; Ivan Ischenko; Qi Bao; Bettina Schwarz; Hanno Nieß; Yan Wang; Andrea Renner; Josef Mysliwietz; Karl-Walter Jauch; Peter J Nelson; Joachim W Ellwart; Christiane J Bruns; Peter Camaj
Journal:  Target Oncol       Date:  2015-02-03       Impact factor: 4.493

5.  Plasma miR-221/222 Family as Novel Descriptive and Prognostic Biomarkers for Glioma.

Authors:  Rui Zhang; Bo Pang; Tao Xin; Hua Guo; Yi Xing; Shangchen Xu; Bin Feng; Bin Liu; Qi Pang
Journal:  Mol Neurobiol       Date:  2015-01-31       Impact factor: 5.590

6.  Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology.

Authors:  Lester J Layfield; Hormoz Ehya; Armando C Filie; Ralph H Hruban; Nirag Jhala; Loren Joseph; Philippe Vielh; Martha B Pitman
Journal:  Diagn Cytopathol       Date:  2014-04       Impact factor: 1.582

7.  MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles.

Authors:  Zhongyang Ding; Haorong Wu; Jiaming Zhang; Guorong Huang; Dongdong Ji
Journal:  Tumour Biol       Date:  2014-06-02

8.  Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification.

Authors:  Katie Partyka; Mitchell McDonald; Kevin A Maupin; Randall Brand; Richard Kwon; Diane M Simeone; Peter Allen; Brian B Haab
Journal:  J Proteome Res       Date:  2012-04-04       Impact factor: 4.466

Review 9.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

Review 10.  Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas.

Authors:  Aadhithya Raman; Anne Marie Lennon
Journal:  Visc Med       Date:  2018-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.